Literature DB >> 8528960

Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector.

K Uçar1, R C Seeger, P M Challita, C T Watanabe, T L Yen, J P Morgan, R Amado, E Chou, T McCallister, J R Barber.   

Abstract

The majority of human neuroblastomas express low to undetectable levels of major histocompatibility complex (MHC) class I and II antigens (MHC-I and -II). We studied the effects of gamma interferon (gamma-IFN) transduction on expression of these antigens in six human neuroblastoma cell lines with and without genomic amplification of the N-myc oncogene. All six were stably transduced with an MoMLV-based gamma-IFN retroviral vector (DAh gamma-IFN). G418-resistant cells were assayed for MHC-I, MHC-II, B7-1, and neuroblastoma-associated antigen expression, as well as for gamma-IFN levels in cell culture supernatants. Sustained gamma-IFN production, 2 to > 1000 units/10(6) cells/d, was attained for five of six transduced cell lines and persisted for up to 9 months. This resulted in marked upregulation of MHC-I and MHC-II expression in LA-N-1, LA-N-6, and CHLA-127 cells and moderate upregulation in SK-N-Fi and SK-N-AS cells. One cell line (LA-N-1) had marked induction of MHC-I and MHC-II despite marginal levels of gamma-IFN production. Expression of CD28 ligand B7-1 (as determined by BB1 antibody) remained unchanged in all gamma-IFN-transduced cell lines tested. Expression of several neuroblastoma-associated antigens (NKH1A, 126-4, HSAN 1.2, HNK, 459, and 390) was upregulated in some of the gamma-IFN-transduced cell lines. These results demonstrate that preparation of gamma-IFN expressing neuroblastoma cells for immunotherapeutic purposes is feasible and that gamma-IFN transduction results in phenotypic changes that may improve immunogenicity of human neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528960

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

2.  FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.

Authors:  Michael L Megison; Jerry E Stewart; Hugh C Nabers; Lauren A Gillory; Elizabeth A Beierle
Journal:  Clin Exp Metastasis       Date:  2012-12-04       Impact factor: 5.150

3.  Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Authors:  Jerry E Stewart; Xiaojie Ma; Michael Megison; Hugh Nabers; William G Cance; Elena V Kurenova; Elizabeth A Beierle
Journal:  Mol Carcinog       Date:  2013-07-19       Impact factor: 4.784

4.  Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry Stewart; Carl Nyberg; Angelica Trujillo; William G Cance; Vita M Golubovskaya
Journal:  Cell Cycle       Date:  2010-03-14       Impact factor: 4.534

5.  Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity.

Authors:  I Airoldi; R Meazza; M Croce; E Di Carlo; T Piazza; C Cocco; T D'Antuono; V Pistoia; S Ferrini; M V Corrias
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

6.  Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.

Authors:  I Airoldi; S Lualdi; S Bruno; L Raffaghello; M Occhino; C Gambini; V Pistoia; M V Corrias
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

7.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma.

Authors:  Lauren A Gillory; Michael L Megison; Jerry E Stewart; Elizabeth Mroczek-Musulman; Hugh C Nabers; Alicia M Waters; Virginia Kelly; Jennifer M Coleman; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.